Biweekly Gemcitabine and Docetaxel as First Line Therapy for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

NCT00906061 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

76

Enrollment

OTHER

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Gemcitabine and Docetaxel

Sponsor

Hospital Arnau de Vilanova